2016 Head and Neck Cancer Symposium

Head and Neck Cancer

Immunotherapy for Head and Neck Cancer: ‘The Fourth Modality Has Arrived’

“This is a big deal. This is going to change all of oncology, not just head and neck cancer,”1 Tanguy ­Seiwert, MD, remarked following a summary by Jeffrey Sosman, MD, on advances in immunotherapy for...

Head and Neck Cancer

Markedly Improved Toxicity Rates With Proton-Beam Reirradiation for Recurrent Head and Neck Cancer

Proton-beam radiation therapy may be an attractive option for reirradiation of recurrent head and neck cancer, with encouraging disease control and survival rates and improved toxicity rates compared ...

Head and Neck Cancer

Late Toxicity Improved With Response-Adapted Volume De-escalation in Locally Advanced Head and Neck Cancer

Efforts to reduce the late toxicity associated with chemoradiotherapy for locally advanced head and neck squamous cell cancer have focused on radiation therapy dose de-escalation in select populations...

Head and Neck Cancer

Study Supports an Immune Effect of Chemoradiation in Head and Neck Cancer

Definitive radiation, with or without chemotherapy, induces a combination of immune-stimulating and inhibitory effects in patients with squamous cell carcinoma of the head and neck, according to resea...

Head and Neck Cancer

Mutational Profile May Impact Treatment Decisions for Smokers With Human Papillomavirus–Positive Oropharyngeal Cancer

Smokers whose oropharyngeal tumors are positive for the human papillomavirus (HPV) might need more aggressive treatment for their disease, according to research presented by Jose Zevallos, MD, at the ...

2016 Head and Neck Cancer Symposium: Induction Chemotherapy Does Not Predict Survival Advantage Over Concurrent Chemoradiation

Head and neck cancer patients who receive induction chemotherapy rather than the standard treatment of concurrent chemoradiation do not benefit from increased survival rates and are less likely to rec...

2016 Head and Neck Cancer Symposium: Chemoradiation May Increase Survival for a Subset of Elderly Head and Neck Cancer Patients

The addition of chemotherapy to radiation therapy improves survival rates among a subset of elderly head and neck cancer patients, specifically those aged 71 to 79 with low comorbidity scores and adva...

2016 Head and Neck Cancer Symposium: Most Recurrences of HPV-Positive Oropharyngeal Cancer Can Be Found Within 6 Months

For patients treated with definitive radiation therapy for oropharyngeal cancer caused by human papillomavirus (HPV), the majority of recurrences can be detected by post-treatment imaging at 3 months ...

2016 Head and Neck Cancer Symposium: Uninsured and Medicaid Patients More Likely to Present With Advanced Tumors, Experience Cancer-Specific Mortality

Compared to patients with non-Medicaid insurance, uninsured patients and patients with Medicaid are more likely to present with advanced stages of head and neck cancer and have higher overall and canc...

head and neck cancer
cost of care

2016 Head and Neck Cancer Symposium: Cost-Coping Strategies and Perceived Social Isolation in Locally Advanced Head and Neck Cancer

The majority of patients with locally advanced head and neck cancers rely on cost-coping strategies that alter their lifestyle in order to manage the financial burden of their care, according to resea...

head and neck cancer
issues in oncology

2016 Head and Neck Cancer Symposium: Study Maps Distinct Molecular Signatures of HPV-Positive Throat Cancer by Smoking Status

Patients with throat cancer exposed to both human papillomavirus (HPV) and tobacco smoke demonstrate a pattern of mutations along several key cancer genes, according to research presented by Zevallos ...




click me